explore -WSS

explore

author：entertainment 2025-09-28 23:10:58 - browse：87183

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Hospital chaplains balance Covid safety with patients’ spiritual needs

WSS

ALS treatment from Biogen, Ionis fails in study

A preacher's new calling: Diversifying neuroscience research

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Supreme Court to hear if Covid misinformation is protected speech

CVS is willing to dump 10% of its Medicare Advantage members

JPM pitch from hospitals? Revenue streams outside of patient care

explore

explore

focus

Continuity nursing helped my family in our darkest PICU moments

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Virginia high school admissions case could be legal follow

CVS is willing to dump 10% of its Medicare Advantage members

DIEP, the 'gold standard' of breast reconstruction, is under threat

Fertility clinic egg and embryo storage is a disaster

Peter Hotez and the public health issue of online harassment

Medicare Advantage overpayments discussion gets experts fired up

Guidelines to prevent youth baseball injuries need more muscle

Nonprofit, backed by Microsoft, to certify AI tools in health care

knowledge

JPM pitch from hospitals? Revenue streams outside of patient care

Boston hospital trains restaurant workers on naloxone for overdoses

At JPM 2024, hospital systems pitch financial strength to investors

Life science postdocs should get big pay hike, NIH panel says

Medicare Advantage overpayments discussion gets experts fired up

Ripples from Flovent's discontinuation is killing children with asthma

Wikipedia

hotspot

hotspot

knowledge